---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-111290"
form_type: "8-K"
ticker: "ISPC"
cik: "0001558569"
company_name: "iSpecimen Inc."
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:16:55.445989+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# iSpecimen names Yuying Liang CFO, unveils plan to expand cancer biospecimen procurement

## Summary
- Appointed Yuying Liang as CFO effective Dec 13, 2024; monthly fee of $25k under engagement with his professional corp.
- Strategic 2025 initiatives focus on procuring high-demand cancer biospecimens through expanded partnerships.
- Plans to establish referral program with international genomic sequencing partner; iSpecimen to be preferred provider.
- Targeting new partnerships with U.S. cancer centers for domestic blood products, with 2025 launch.
- Will expand portfolio with remnant biofluid offerings from recently partnered sites, including diagnostic codes.

## SEC filing metadata
- accession: 0001213900-24-111290
- form_type: 8-K
- ticker: ISPC
- cik: 0001558569
- company_name: iSpecimen Inc.
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1558569/000121390024111290/0001213900-24-111290-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1558569/000121390024111290/ea0225487-8k_ispecimen.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-111290
- JSON: https://secwatch.observer/filing/0001213900-24-111290.json
- Plain text: https://secwatch.observer/filing/0001213900-24-111290.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.